Protein / target

Tumor necrosis factor receptor superfamily member 11B

Encoded byTNFRSF11BO00300Homo sapiensSwiss-Prot

UniProt: O00300 Ensembl: ENSG00000164761 HGNC: HGNC:11909 NCBI Gene: 4982

Antibody-tractable

Druggability

GO CC high conf

Research papers

Protein at a glance

Biological role

Signaling receptor

Strongest disease association

Hypothyroidism

Via encoding gene TNFRSF11B · Genetic evidence · score 0.75

Research activity

Emerging research

1 papers · latest 2001

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis.

View complete UniProt function annotation

Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis

Subcellular location

Secreted

Domains and Gene Ontology detail (12)

Domains & features

Death 1Death 2

Gene Ontology

Cextracellular matrix
Cextracellular region
Cextracellular space
Cplasma membrane
Fcytokine activity
Fheparan sulfate binding
Fsignaling receptor activity
Papoptotic process
Psignal transduction
Pskeletal system development

401 aa · 46 kDa

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TNFRSF11B

Gene-level evidence surfaced through the gene TNFRSF11Bthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Osteoporosis

0.81Well supported

Genetic evidence dominant · Open Targets 0.47

Hypothyroidism

0.76Well supported

Genetic evidence dominant · Open Targets 0.47

Myxedema

0.63Moderately supported

Genetic evidence dominant · Open Targets 0.38

Nasal Polyps

0.60Moderately supported

Genetic evidence dominant · Open Targets 0.37

Fractures, Bone

0.57Moderately supported

Genetic evidence dominant · Open Targets 0.34

View evidence synthesis (5)

OsteoporosisWell supported

0.81

agreement 0.69–0.93

Genetic67%Animal model21%Literature12%

Open Targets aggregate 0.47 · 3 independent evidence families

HypothyroidismWell supported

0.76

agreement 0.62–0.90

Genetic95%Literature5%

Open Targets aggregate 0.47 · 2 independent evidence families

MyxedemaModerately supported

0.63

agreement 0.51–0.74

Genetic100%

Open Targets aggregate 0.38 · 1 independent evidence family

Nasal PolypsModerately supported

0.60

agreement 0.46–0.74

Genetic100%Literature1%

Open Targets aggregate 0.37 · 2 independent evidence families

Fractures, BoneModerately supported

0.57

agreement 0.43–0.71

Genetic97%Literature3%

Open Targets aggregate 0.34 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Osteoporosis0.47

Hypothyroidism0.47

Myxedema0.38

Nasal Polyps0.37

Fractures, Bone0.34

Bone Diseases0.32

Autoimmune Diseases0.30

Thyroid Diseases0.27

Hashimoto's Disease0.26

Tractability

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (3)

AB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosisClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

1 papers · to 2001

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Minireview: the OPG/RANKL/RANK system.953 cites

Khosla S · Endocrinology · 2001

Recent

Minireview: the OPG/RANKL/RANK system.

Khosla S · Endocrinology · 2001

Europe PMC papers linked directly to this protein.